Product Name: PTEN-1 (185-199)
Product Number: PE-01BBM99
Size: 200 µg      Price:51.00
1 mg      $US102.00
5 mg      224.00
Peptide Name: PTEN1 (185-199)

Product Use: Services as a blocking peptide for use with the PTEN-1 rabbit polyclonal antibody (Cat. No.: AB-NP023-3) that is also available from Kinexus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CHLDYRPVALLFHKMM

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1973.4 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: PTEN-1 pan-specific antibody (Cat. No.: AB-NP023-3)

Scientific Background: PTEN is a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins, and also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for the tumor suppressor function of PTEN. It antagonizes the PI3K-AKT/PKB signalling pathway by dephosphorylating phosphoinositides, and inhibits cell cycle progression and cell survival. The unphosphorylated form of PTEN cooperates with AIP1 to suppress Akt1 activation. It dephosphorylates tyrosine-phosphorylated focal adhesion kinase (FAK) and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. It plays a role as a key modulator of the AKT-mTOR signalling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis. It acts as negative regulator of insulin signalling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability. In motile cells, PTEN suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement.